Cytori Therapeutics (NASDAQ: CYTX) reported Q4 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.56 million versus the consensus estimate of $3.18 million.

2016 Financial Guidance

• Operating cash burn within a range of $18 million to $20 million
• Total revenues (product and contract) within a range of $12 million to $14 million

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.